## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($239.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. FDA clearances: Medtronic, Insulet, Resmed**
- Source: Modern Healthcare | 20251211T110844 | Somewhat-Bullish | Relevance: 99%
-  The FDA has cleared new medical devices from Medtronic, Insulet, and Resmed. This article briefly mentions these clearances.

**2. Jump Financial LLC Takes Position in ResMed Inc. $RMD**
- Source: MarketBeat | 20251210T113853 | Somewhat-Bullish | Relevance: 99%
-  Jump Financial LLC newly acquired 22,137 shares of ResMed Inc. (NYSE:RMD), valued at approximately $5.71 million, as per its latest SEC filing. Several other hedge funds have also adjusted their holdings in ResMed, with institutional investors collectively owning 54.98% of the company's stock. The article also details recent analyst ratings, insider transactions, and financial performance data for ResMed.

**3. Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy**
- Source: KFOR | 20251209T020952 | Bullish | Relevance: 99%
-  Resmed has received FDA clearance for Smart Comfort, an AI-enabled medical device designed to personalize CPAP therapy for individuals with obstructive sleep apnea (OSA). This technology uses machine learning and real-world sleep data to recommend individualized comfort settings, aiming to improve therapy adherence and patient experience. Smart Comfort is set to launch as a limited beta in early 2026, with a broader rollout later that year.

**4. Cerity Partners LLC Acquires 29,205 Shares of ResMed Inc. $RMD**
- Source: MarketBeat | 20251211T092340 | Somewhat-Bullish | Relevance: 98%
-  Cerity Partners LLC significantly increased its stake in ResMed Inc. by 184.1% in the second quarter, purchasing an additional 29,205 shares. This increased their total holdings to 45,071 shares valued at $11.628 million. Other institutional investors also adjusted their positions in ResMed, while company insiders made several stock sales.

**5. ResMed Inc. $RMD Stock Position Raised by Axa S.A.**
- Source: MarketBeat | 20251210T090917 | Bullish | Relevance: 98%
-  Axa S.A. significantly increased its stake in ResMed Inc. (NYSE:RMD) by 76.6% during the second quarter, now owning 112,977 shares valued at $29.15 million. Other institutional investors have also adjusted their positions in RMD, while several insiders have sold shares. Analysts maintain a "Moderate Buy" rating for ResMed with a consensus target price of $297.45.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 17 ($5.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $5.0M in recent transactions.
2. Elevated short interest (8.2%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Forward P/E 21.0x stretched relative to 10% growth. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $36.8B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 21.0 |
| Current P/E | 23.1 |
| YoY Growth | 10.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -0.1% (minimal 5-day change). Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Below SMA200 (1.00x), long-term trend not supportive. MACD histogram positive (0.63), confirming momentum. RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.06% (CS: 38) | Neutral |
| RSI_14 | 49.7 | Neutral |
| MACD Histogram | 0.63 | Bullish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 0.978x | Below |
| vs SMA200 | 0.997x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $252.39
- **Stop Loss:** $239.55 (5.1% risk)
- **Target:** $265.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 107
- **Position Value:** $27,005.73
- **Portfolio %:** 27.01%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*